after enrollment, you are assigned to receive either gb-0895 or a placebo (0.9% sodium chloride) in a double‑blind manner, meaning neither you nor the study staff know which you receive.

the assignment is made by a computer system to ensure fairness.

before the first injection, measurements of lung function (forced expiratory volume in 1 second, fev1) are taken.

questionnaires about asthma control and quality of life are completed.

a daily symptom diary is started to record daytime and nighttime asthma symptoms.

you receive a single subcutaneous injection (injection under the skin) of 300 mg of gb-0895 or the placebo solution.

the injection is performed by a trained professional in a clinical setting.

throughout the 52‑week study period, you attend scheduled clinic visits, typically every four weeks, for safety checks and to receive the next injection.

each injection contains the same dose of 300 mg of gb-0895 or the placebo, as determined by the initial randomization.

each day you record asthma symptoms in the diary, noting both daytime and nighttime experiences.

these entries are used to evaluate changes in symptom scores over time.

at designated visits, including the final visit at week 52, lung function tests (fev1) are repeated.

questionnaires on asthma control (acq‑6) and quality of life (aqlq) are completed again to assess any changes.

at the end of the 52‑week period, a final evaluation is performed to summarize the effect of the treatment on the annualized asthma exacerbation rate and other outcomes.

after the final assessments, the study participation concludes.